arrow
D

Douglas MacDonald

royal free london nhs foundation trust
H指数:25
被引数:2,688

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell lines

扩增的适应性NKG2C+ NK细胞对HBV感染的肝癌细胞系表现出强大的ADCC和功能反应。

2025-10-250
OAAI
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo

基于全人源T细胞受体模拟抗体的CAR T细胞在体内表现出强大的抗肿瘤活性。

2025-03-260
PRE
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

通过CD3亲和力调节产生具有细胞因子释放和生物分布的分化特征的T细胞重定向双特异性抗体

2021-07-1364
OAAI
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
2020-06-2466
PREAI
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

一类增强CD3-bispecific抗体抗肿瘤活性的共刺激CD28-bispecific抗体

2020-01-0894
OAAI
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties
2019-12-264
OAAI
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice
2019-11-0164
OAAI
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
2019-06-19100
OAAI
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype
2018-11-30138
OA
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
2017-05-02125
OAAI
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes
2016-05-2735
OAAI
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
2015-12-11195
OAAI